Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.
Target Price
The average target price of VVOS is 2.19 and suggests 461% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre